Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 15, 2014

Primary Completion Date

March 9, 2017

Study Completion Date

February 9, 2018

Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIOLOGICAL

Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells

Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.

BIOLOGICAL

Plasma-Lyte A

Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.

Trial Locations (6)

15213

University of Pittsburgh, Pittsburgh

43210

Ohio State University, Columbus

55108

University of Minnesota Medical Center, Saint Paul

94143

University of California San Francisco, San Francisco

94305

Stanford University, Stanford

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Massachusetts General Hospital

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Minnesota

OTHER

collaborator

Ohio State University

OTHER

lead

Michael A. Matthay

OTHER

NCT02097641 - Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START) | Biotech Hunter | Biotech Hunter